NTLA$12.475.74%-0.76
After Hours: 12.35-0.12 -0.96%
Intellia Therapeutics Inc (NTLA)
Date: 2026-10-30 16:00O: 12.88H: 13.16L: 12.04C: 12.47Vol: 4.073M
Intellia Therapeutics Inc stock is traded at $12.47, with a volume of 4,072,984. It is down -5.74% in the last 24 hours and up +3.40% over the past month. Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Previous Close:
$13.23
Open:
$12.88
24h Volume:
4,072,984
Relative Volume:
1.11
Market Cap:
$1.75B
Revenue:
$67.67M
Net Income/Loss:
-$412.69M
P/E Ratio:
-
EPS:
-$3.83
Net Cash Flow:
-$395.87M
1W Performance:
+11.24%
1M Performance:
+3.40%
6M Performance:
-7.49%
1Y Performance:
+1.67%
1-Day Range:
$12.04$13.16
1-Week Range:
$11.17$13.94
52-Week Range:
$7.95$18.48
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
857-285-6200Address
40 ERIE STREET, CAMBRIDGE, MA, USACompare NTLA vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA Intellia Therapeutics Inc | $12.47 | $1.75B | $67.67M | -$412.69M | -$395.87M | -$3.83 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Intellia Therapeutics Inc Stock (NTLA) Insider Trading
- ELIANA CLARKOct 05 '26Officer
- Transaction
- Proposed Sale
- Cost
- $12.75
- #Shares
- 57,750
- Value ($)
- 736,312
- #Shares Total
- 0
- LEONARD JOHN MAug 21 '26President and CEO
- Transaction
- Sale
- Cost
- $13.00
- #Shares
- 2,785
- Value ($)
- 36,205
- #Shares Total
- 1,147,064
- LEONARD JOHN MAug 20 '26Officer
- Transaction
- Proposed Sale
- Cost
- $12.95
- #Shares
- 22,675
- Value ($)
- 293,641
- #Shares Total
- 0
- LEONARD JOHN MAug 20 '26President and CEO
- Transaction
- Sale
- Cost
- $12.60
- #Shares
- 19,890
- Value ($)
- 250,614
- #Shares Total
- 1,149,849
- Dulac Edward J IIIJul 22 '26EVP, Chief Financial Officer
- Transaction
- Sale
- Cost
- $11.25
- #Shares
- 8,111
- Value ($)
- 91,249
- #Shares Total
- 148,175
- Dulac Edward J IIIJul 02 '26EVP, Chief Financial Officer
- Transaction
- Sale
- Cost
- $18.00
- #Shares
- 4,677
- Value ($)
- 84,186
- #Shares Total
- 156,286
- EDWARD DULACJul 02 '26Officer
- Transaction
- Proposed Sale
- Cost
- $17.24
- #Shares
- 4,677
- Value ($)
- 80,631
- #Shares Total
- 0
- Dube Michael PJul 01 '26VP, Chief Accounting Officer
- Transaction
- Sale
- Cost
- $16.78
- #Shares
- 2,641
- Value ($)
- 44,316
- #Shares Total
- 66,886
- BASTA JAMESMar 02 '26EVP, General Counsel
- Transaction
- Sale
- Cost
- $13.78
- #Shares
- 1,211
- Value ($)
- 16,688
- #Shares Total
- 156,794
- Clark ElianaMar 02 '26EVP, Chief Technical Officer
- Transaction
- Sale
- Cost
- $13.78
- #Shares
- 607
- Value ($)
- 8,364
- #Shares Total
- 93,864
